Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis.
Level 5 - mechanism / opinion, no new human data
Narrative review evaluating biological mechanisms and summarized institutional experience without systematic review methodology
PubMed 28902419 · doi:10.1002/hep.29521
What was done
The authors conducted a narrative review evaluating the theoretical and clinical risks of using blood donated by patients with hereditary hemochromatosis during therapeutic phlebotomy. They assessed biological data regarding infectious risks from siderophilic organisms (such as Yersinia enterocolitica), historical concerns regarding nonvoluntary donor risk, and clinical experiences from blood centers that allow hemochromatosis donors.
What was found
The abstract reports no quantitative data or specific numerical safety metrics. Based on biological data and summarized institutional experiences, the authors found no convincing evidence to justify excluding hereditary hemochromatosis patients from the blood donor pool.
Why it matters
Many blood centers continue to discard blood collected during therapeutic phlebotomies due to theoretical infection concerns. Synthesizing evidence supporting its safety provides a rationale to harmonize policies and expand the available donor blood supply.
Limits
This is a narrative review with no primary empirical data, quantitative synthesis, or systematic search methodology described in the abstract. Exact sample sizes, infection incidence figures, and comparative risk estimates from participating centers are not provided.
Cited by
- supports Periodic blood donation helps manage iron overload in people with hemochromatosis.